Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
71.50    1.50 (2.14%)
Bid:
71.00
Ask:
72.00
Spread: 1.00 (1.408%)
Market Cap: £325.40m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Final Results

12 Dec 2008 12:06

RNS Number : 0481K
Avacta Group PLC
12 December 2008
 



Avacta Group plc

Audited Results for the year to 31 July 2008

On 4 November 2008, Avacta Group plc ("Avacta", the "Group" or the "Company") announced its preliminary results for the year to 31 July 2008. The preliminary results included intangible assets of £7,144,000 and an other reserve of £1,834,000 reflecting the application of reverse acquisition accounting of the transaction whereby Avacta Limited reversed into Avacta Group plc (formerly Readybuy plc) during August 2006. Upon conversion from accounting under United Kingdom Generally Accepted Accounting Practice to International Financial Reporting Standards as adopted by the European Union, it is possible to recognise a different treatment of this transaction within the financial statements, which the Directors believe to be beneficial.

There is no impact on the income statement or the cash flows of the Group in either the current or comparative accounting period

Accordingly, the consolidated balance sheet of the Group has been adjusted from that included within the Preliminary Announcement to reflect this revised treatment resulting in goodwill of £3,563,000 that had been previously recognised within the intangible assets of £7,144,000 now being recognised within the other reserveThe adjusted consolidated balance sheet is included within this announcement. 

There are no other changes to the Preliminary Announcement.

The Company's full Annual Report & Accounts are available on its website at www.avacta.com

Enquiries:

Avacta Group plc

087 0835 4367

Alastair Smith, Chief Executive Officer

Tim Sykes, Chief Financial Officer

Daniel Stewart & Company plc

020 7776 6550

Lindsay Mair / Charlotte Stranner

Novum Securities Limited

020 7562 4700

Henry Turcan

Haggie Financial LLP

020 7417 8989

Nicholas Nelson / Kathy Boate

   

   Consolidated Balance Sheet as at 31 July 2008

2008

2007

£000

£000

Non-current assets

Property, plant & equipment

290

148

Intangible assets

3,581

-

-------------

------------

3,871

148

-------------

------------

Current assets

Trade and other receivables

92

170

Income taxes

84

-

Cash and cash equivalents

1,097

2,527

-------------

------------

1,273

2,697

-------------

------------

Total assets

5,144

2,845

-------------

------------

Current liabilities

Trade and other payables

(234)

(164)

Finance lease obligations

(11)

(11)

-------------

------------

(245)

(175)

-------------

------------

Non-current liabilities

Finance lease obligations

(30)

(41)

-------------

------------

(30)

(41)

-------------

------------

Total liabilities

(275)

(216)

-------------

------------

Net assets

4,869

2,629

-------------

------------

Equity attributable to equity holders of the Company

Called up share capital

900

856

Share premium account

6,524

4,882

Other reserve

(1,729)

(1,729)

Capital reserve

1,899

-

Retained earnings

(2,725)

(1,380)

-------------

------------

Total equity

4,869

2,629

-------------

------------

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR EAAAAFEDPFFE
Date   Source Headline
13th Nov 20197:00 amRNSLG Chem Life Sciences Expands Partnership
11th Nov 20197:00 amRNSHolding(s) in Company
8th Nov 20196:30 pmRNSHolding(s) in Company
8th Nov 20196:26 pmRNSHolding(s) in Company
7th Nov 20191:00 pmRNSHolding(s) in Company
7th Nov 201911:00 amRNSHolding(s) in Company
6th Nov 20192:30 pmRNSHolding(s) in Company
4th Nov 20191:18 pmRNSResult of General Meeting
18th Oct 201912:06 pmRNSProposed Placing & Subscription to raise up to £9M
18th Oct 201912:05 pmRNSInterim Results for the Period Ended 31 July 2019
10th Oct 20197:00 amRNSCollaboration with ADC Therapeutics
5th Aug 20199:05 amRNSSecond Price Monitoring Extn
5th Aug 20199:00 amRNSPrice Monitoring Extension
29th Jul 20197:00 amRNSAvacta's CEO to Present at Biotech Investor Day
20th Jun 20197:00 amRNSAvacta and Selexis Partner to Develop Cell Line
19th Jun 20197:00 amRNSTurner Pope Investor Evening
12th Jun 20197:00 amRNSAvacta's CSO to Present at Major US Conference
10th Jun 20197:00 amRNSAvacta hits Clinical Candidate Selection Milestone
3rd Jun 20197:00 amRNSTMAC Programme Accelerates
23rd Apr 20193:48 pmRNSIssue of Equity
12th Apr 20192:46 pmRNSHolding(s) in Company
9th Apr 20197:00 amRNSInterim Results
8th Mar 201912:14 pmRNSIssue of Equity
6th Feb 201912:27 pmEQSHardman & Co Research: Avacta (AVCT): A second wake-up call for the market
4th Feb 20197:00 amRNSModerna Exercises Exclusive Product License Option
28th Jan 20197:00 amRNSDirector Appointment
21st Jan 20193:40 pmRNSResult of Annual General Meeting
21st Jan 20197:00 amRNSAGM Business Update and Notice of Results
18th Jan 20195:08 pmRNSShare Incentive Plan/Issue of Equity
9th Jan 201911:06 amRNSHolding(s) in Company
7th Jan 20192:50 pmRNSDirector/PDMR Shareholdings
3rd Jan 20198:56 amRNSHolding(s) in Company
2nd Jan 20197:00 amRNSDirector/PDMR Shareholding
21st Dec 20181:41 pmRNSHolding(s) in Company
19th Dec 20183:32 pmRNSHolding(s) in Company
17th Dec 20187:00 amRNSAvacta London Science Day
12th Dec 201812:50 pmRNSHolding(s) in Company
12th Dec 201812:44 pmRNSHolding(s) in Company
12th Dec 20187:00 amRNSAppointment of Chief Medical Officer
11th Dec 20187:00 amRNSPosting of Annual Report and Notice of AGM
10th Dec 20182:05 pmRNSSecond Price Monitoring Extn
10th Dec 20182:00 pmRNSPrice Monitoring Extension
10th Dec 20187:30 amEQSHardman & Co Research: Avacta (AVCT): Wake-up call for the market
10th Dec 20187:00 amRNSDevelopment Partnership with LG Chem Life Sciences
12th Nov 20187:00 amRNSAvacta to Present at Major European Conference
11th Oct 20187:00 amRNSAvacta's CTO to Present at Major US Conference
10th Oct 20187:00 amRNSAvacta agrees Affimer reagent licensing deal
2nd Oct 20187:00 amRNSPreliminary Results
21st Sep 20187:00 amRNSInvestor Meeting and Presentation
5th Sep 20187:15 amEQSHardman & Co Research: Avacta (AVCT): Capital increase for further development

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.